Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

NCT02105766 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

56

Enrollment

NIH

Sponsor class

Conditions

Sickle Cell Disease
Thalassemia
Stem Cell Transplantation
Graft vs Host Disease

Interventions

DRUG: Alemtuzumab
DRUG: Sirolimus
DRUG: Cyclophosphamide
DRUG: Pentostatin
PROCEDURE: Radiotherapy
DRUG: Filgrastim

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborators

[object Object]
[object Object]